Drug intelligence / Profile preview

SHR-3276

Development stage: Phase 2
Lead developer: Suzhou Suncadia Biopharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

SHR-3276 is an investigational antineoplastic drug developed by Suzhou Suncadia Biopharmaceuticals. It is currently in Phase 1/2 clinical trials for the treatment of advanced solid tumors (neoplasms). The drug is administered intravenously and is being evaluated for its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced malignant tumors who have failed standard treatments or have no effective standard options available. The precise mechanism of action has not been disclosed as of the latest updates.

Beyond the preview

Go deeper on SHR-3276.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-3276.

Explore the full profile